BioSpace News Archive

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293.

Signifier Medical Technologies’ eXciteOSA®, the Only FDA-Authorized Daytime Therapy for Primary Snoring and Mild Obstructive Sleep Apnea, Demonstrates Real-World Adherence to Treatment of Over 80%.

Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX: ASP; OTCQB: ASPCF) today announced that the Board of Directors has determined to undertake a strategic review of capital and business alternatives, including a possible debt or equity financing, asset sale, M&A, or licensing transaction.

Araris Biotech AG today announced the company’s chief executive officer, Philipp Spycher, Ph.D., will be a speaker at the Next Generation Protein Therapeutics Summit hosted by Informa Connect.

JDRF , the leading global type 1 diabetes (T1D) research and advocacy organization, announces the launch of the Type 1 Diabetes Index (T1D Index).

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will present a corporate update at Roivant’s Investor Day, taking place on September 28th, 2022.

MaxCyte, Inc. announced that it has relocated its headquarters to 9713 Key West Avenue in Rockville, Maryland, 20850, within Maryland’s I-270 Biotech Corridor.

Mapi Pharma Ltd. announced today positive top-line results from the GA Depot (a long acting glatiramer acetate) Phase III clinical trial assessing the efficacy, safety and tolerability of a once monthly GA Depot 40 mg compared to placebo in relapsing forms of multiple sclerosis (RMS) patients.

Cybin Inc. is pleased to announce its participation in the following upcoming conferences.

AbCellera (Nasdaq: ABCL) today announced it has launched the second phase of its global headquarters expansion by breaking ground on its new facility in Vancouver, Canada.